Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity
Autore:
Llerena, A; Berecz, R; de la Rubia, A; Norberto, MJ; Benitez, J;
Indirizzi:
Univ Extremadura, Sch Med, Dept Pharmacol & Psychiat, E-06071 Badajoz, Spain Univ Extremadura Badajoz Spain E-06071 Psychiat, E-06071 Badajoz, Spain Hosp Psychiat, Unit Res & Clin Psychopharmacol, Merida, Spain Hosp Psychiat Merida Spain it Res & Clin Psychopharmacol, Merida, Spain
Titolo Testata:
THERAPEUTIC DRUG MONITORING
fascicolo: 4, volume: 22, anno: 2000,
pagine: 397 - 401
SICI:
0163-4356(200008)22:4<397:UOTMRA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFORMANCE LIQUID-CHROMATOGRAPHY; PLASMA-LEVELS; HYDROXYLATION PHENOTYPE; DRUG-METABOLISM; THIORIDAZINE; MEPHENYTOIN; DEBRISOQUIN; ENANTIOMERS; INHIBITION; GENOTYPE;
Keywords:
thioridazine; high-pressure liquid chromatography; CYP2D6; therapeutic drug monitoring (TDM); pharmacogenetics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Benitez, J Univ Extremadura, Sch Med, Dept Pharmacol & Psychiat, Av de Elvas S-N, E-06071 Badajoz, Spain Univ Extremadura Av de Elvas S-N Badajoz Spain E-06071 , Spain
Citazione:
A. Llerena et al., "Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity", THER DRUG M, 22(4), 2000, pp. 397-401

Abstract

Thioridazine is metabolized in humans by CYP2D6 to mesoridazine, which is an active metabolite. Two or more CYP2D6 substrates are seldom given simultaneously to elderly patients because potentially dangerous metabolic interactions may occur. It map be valuable to know the CYP2D6 metabolic capacity of such patients to avoid drug interactions, which depend on the metabolic phenotype. The goal of this study was to evaluate the use of the mesoridazine/thioridazine ratio for the estimation of CYP2D6 enzyme capacity. A sensitive and reliable method has been developed for the determination of thioridazine and its metabolites, mesoridazine and sulforidazine. Commonly used central nervous system (CNS) comedications do not interfere with the method. A group of 27 chronic patients with mental illness receiving monotherapy with thioridazine were studied. There were 23 men and 4 women between 37 and80 years old (mean +/-SD: 61.2 +/- 10.2). The thioridazine/mesoridazine ratio correlated with the debrisoquine metabolic ratio (r = 0.74, p < 0.001). Therefore, the authors suggest that the measurement of thioridazine and its metabolite might be a useful tool to assess CYP3D6 activity during treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 22:23:34